Takara Bio completes absorption of ViSpot subsidiary

Takara Bio (TSE:4974) announced the completion of its absorption-type merger with ViSpot Corporation. As the surviving company, Takara Bio aims to streamline operations and accelerate business expansion through this merger. ViSpot, specializing in virus safety evaluation testing, ceases to exist as a separate entity. The merger is expected to have a negligible impact on Takara Bio's consolidated financial results. ViSpot’s capital stood at JPY40 million as of February 2025, and it was originally established in September 2017.